Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
606
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn Disease
Interventions
DRUG:
Ozanimod
OTHER:
Placebo
Sponsor
Celgene